- Home
- LZ vs PHVS Comparison
LZ vs PHVS Comparison
Compare LZ & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZ
- PHVS
- Stock Information
- Founded
- LZ 2001
- PHVS 2015
- Country
- LZ United States
- PHVS Switzerland
- Employees
- LZ N/A
- PHVS N/A
- Industry
- LZ EDP Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- LZ Technology
- PHVS Health Care
- Exchange
- LZ Nasdaq
- PHVS Nasdaq
- Market Cap
- LZ 1.5B
- PHVS 980.3M
- IPO Year
- LZ 2021
- PHVS 2021
- Fundamental
- Price
- LZ $8.98
- PHVS $22.32
- Analyst Decision
- LZ Hold
- PHVS Buy
- Analyst Count
- LZ 8
- PHVS 6
- Target Price
- LZ $9.08
- PHVS $37.17
- AVG Volume (30 Days)
- LZ 1.7M
- PHVS 30.0K
- Earning Date
- LZ 08-06-2025
- PHVS 08-13-2025
- Dividend Yield
- LZ N/A
- PHVS N/A
- EPS Growth
- LZ 72.11
- PHVS N/A
- EPS
- LZ 0.17
- PHVS N/A
- Revenue
- LZ $690,777,000.00
- PHVS N/A
- Revenue This Year
- LZ $8.18
- PHVS N/A
- Revenue Next Year
- LZ $7.23
- PHVS N/A
- P/E Ratio
- LZ $53.57
- PHVS N/A
- Revenue Growth
- LZ 3.25
- PHVS N/A
- 52 Week Low
- LZ $5.33
- PHVS $11.51
- 52 Week High
- LZ $10.60
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- LZ 51.75
- PHVS 73.31
- Support Level
- LZ $8.71
- PHVS $17.63
- Resistance Level
- LZ $9.26
- PHVS $19.00
- Average True Range (ATR)
- LZ 0.23
- PHVS 1.20
- MACD
- LZ 0.02
- PHVS 0.35
- Stochastic Oscillator
- LZ 65.06
- PHVS 92.15
About LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.